Table 1 Demographic, clinical and assay characteristics of HTAN participants
Characteristic | n = 2,088 | ||
|---|---|---|---|
Gender | Tissue or organ of origin | ||
Female | 1,512 (72%) | Breast | 945 (45%) |
Male | 460 (22%) | Lung | 260 (12%) |
Not Reported | 116 (5.6%) | Pancreas | 56 (2.7%) |
Colon | 49 (2.3) | ||
Race | Bone marrow | 38 (1.8%) | |
White | 1,450 (69%) | Sigmoid colon | 35 (1.7%) |
Black or African American | 304 (15%) | Other | 622 (30%) |
Asian | 41 (2.0%) | Not reported | 205 (9.8%) |
Other | 10 (0.5%) | ||
Not reported | 283 (14%) | Assay | |
Bulk DNA-seq | 1,035 (50%) | ||
Ethnicity | H&E | 979 (47% | |
Not Hispanic or Latino | 1,697 (81%) | Bulk RNA-seq | 881 (42%) |
Hispanic or Latino | 41 (2.0%) | sc- or snRNA-seq | 750 (36%) |
Not reported | 350 (17%) | Multiplexed tissue imaging | 443 (21%) |
sc- or snATAC-seq | 267 (12.6%) | ||
Age at diagnosis (years, [25th–75th percentile]) | 51 [31, 63] | Spatial transcriptomics | 232 (11.1%) |
Other | 80 (3.8%) | ||
Primary diagnosis | |||
Ductal carcinoma in situ | 771 (37%) | ||
Adenocarcinoma | 221 (11%) | ||
Ductal carcinoma | 102 (4.9%) | ||
Malignant melanoma | 66 (3.2%) | ||
Carcinoma | 60 (2.9%) | ||
Neuroblastoma | 56 (2.7%) | ||
Other | 396 (19%) | ||
Not reported | 325 (16%) |
